Home » Novartis Takes $120 Million Hit From Failed Cancer Drug Trial
Novartis Takes $120 Million Hit From Failed Cancer Drug Trial
Swiss pharmaceutical company Novartis AG says it has halted late-stage development of a new drug for lung cancer and will write off $120 million in the fourth quarter as a result.
Star Tribune
Star Tribune
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May